Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE
- PMID: 33762727
- DOI: 10.1038/s41581-021-00417-3
Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE
Comment on
-
Avacopan for the Treatment of ANCA-Associated Vasculitis.N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
References
-
- Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020). - DOI
-
- Pepper, R. J. et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology. 58, 260–268 (2019). - PubMed
-
- Jayne, D. R. W. et al. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599–609 (2021). - DOI
-
- Chen, M., Jayne, D. R. W. & Zhao, M. H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 13, 359–367 (2017). - DOI
-
- Xiao, H. et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25, 225–231 (2014). - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
